Antagonists of IAP proteins as cancer therapeutics

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 206-214

  Dynek, Jasmin N ^a   Vucic, Domagoj ^a  

^a GENENTECH INC   (United States)

Author keywords

Antagonist; Apoptosis; C IAP; IAP; SMAC; TNF; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; LCL 161; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER THERAPY; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84876072130     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.06.013     Document Type: Review

References (99)

1. Crook N.E., Clem R.J., Miller L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 1993, 67:2168-2174.
2. Birnbaum M.J., Clem R.J., Miller L.K. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J. Virol. 1994, 68:2521-2528.
3. Clem R.J., Miller L.K. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol. Cell Biol. 1994, 14:5212-5222.
4. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
5. Vucic D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr. Cancer Drug Targets 2008, 8:110-117.
6. Hinds M.G., Norton R.S., Vaux D.L., Day C.L. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat. Struct. Biol. 1999, 6:648-651.
7. Sun C., Cai M., Gunasekera A.H., Meadows R.P., Wang H., Chen J., Zhang H., Wu W., Xu N., Ng S.C., Fesik S.W. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 1999, 401:818-822.
8. Vaux D.L., Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 2005, 6:287-297.
9. Hauser H.P., Bardroff M., Pyrowolakis G., Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. 1998, 141:1415-1422.
10. Chen Z., Naito M., Hori S., Mashima T., Yamori T., Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. 1999, 264:847-854.
11. Blankenship J.W., Varfolomeev E., Goncharov T., Fedorova A.V., Kirkpatrick D.S., Izrael-Tomasevic A., Phu L., Arnott D., Aghajan M., Zobel K., Bazan J.F., Fairbrother W.J., Deshayes K., Vucic D. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2. Biochem. J. 2009, 417:149-160.
12. Gyrd-Hansen M., Darding M., Miasari M., Santoro M.M., Zender L., Xue W., Tenev T., da Fonseca P.C., Zvelebil M., Bujnicki J.M., Lowe S., Silke J., Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat. Cell Biol. 2008, 10:1309-1317.
13. Hofmann K., Bucher P., Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem. Sci. 1997, 22:155-156.
14. Martin S.J. Dealing the CARDs between life and death. Trends Cell Biol. 2001, 11:188-189.
15. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E. Structure of a survivin-borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131:271-285.
16. Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J.E., MacKenzie A., Korneluk R.G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996, 379:349-353.
17. Wilmanski J.M., Petnicki-Ocwieja T., Kobayashi K.S. NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J. Leukoc. Biol. 2008, 83:13-30.
18. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
19. Salvesen G.S., Abrams J.M. Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 2004, 23:2774-2784.
20. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006, 7:988-994.
21. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001, 104:791-800.
22. Sun C., Cai M., Meadows R.P., Xu N., Gunasekera A.H., Herrmann J., Wu J.C., Fesik S.W. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 2000, 275:33777-33781.
23. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R., Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 2003, 11:519-527.
24. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
25. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
26. Verhagen A.M., Coulson E.J., Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001, 2. REVIEWS3009.
27. Eckelman B.P., Salvesen G.S. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J. Biol. Chem. 2006, 281:3254-3260.
28. Vucic D., Franklin M.C., Wallweber H.J., Das K., Eckelman B.P., Shin H., Elliott L.O., Kadkhodayan S., Deshayes K., Salvesen G.S., Fairbrother W.J. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem. J. 2005, 385:11-20.
29. Wilkinson J.C., Wilkinson A.S., Scott F.L., Csomos R.A., Salvesen G.S., Duckett C.S. Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs). A caspase-independent mechanism for apoptotic inhibition. J. Biol. Chem. 2004, 279:51082-51090.
30. Zobel K., Wang L., Varfolomeev E., Franklin M.C., Elliott L.O., Wallweber H.J., Okawa D.C., Flygare J.A., Vucic D., Fairbrother W.J., Deshayes K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 2006, 1:525-533.
31. Schile A.J., Garcia-Fernandez M., Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 2008, 22:2256-2266.
32. Choi Y.E., Butterworth M., Malladi S., Duckett C.S., Cohen G.M., Bratton S.B. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J. Biol. Chem. 2009, 284:12772-12782.
33. Varfolomeev E., Goncharov T., Fedorova A.V., Dynek J.N., Zobel K., Deshayes K., Fairbrother W.J., Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFα)-induced NF-κB activation. J. Biol. Chem. 2008, 283:24295-24299.
34. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., Gillard J.W., Jaquith J.B., Morris S.J., Barker P.A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
35. Mahoney D.J., Cheung H.H., Mrad R.L., Plenchette S., Simard C., Enwere E., Arora V., Mak T.W., Lacasse E.C., Waring J., Korneluk R.G. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. USA 2008, 105:11778-11783.
36. Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M., Rieser E., Feltham R., Vince J., Warnken U., Wenger T., Koschny R., Komander D., Silke J., Walczak H. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 2009, 36:831-844.
37. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007, 131:669-681.
38. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B.A., Koentgen F., Vaux D.L., Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
39. Xu L., Zhu J., Hu X., Zhu H., Kim H.T., LaBaer J., Goldberg A., Yuan J. C-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol. Cell 2007, 28:914-922.
40. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., Choo K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000, 10:1319-1328.
41. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
42. Pohl C., Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell 2008, 132:832-845.
43. Liston P., Fong W.G., Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003, 22:8568-8580.
44. Diez E., Lee S.H., Gauthier S., Yaraghi Z., Tremblay M., Vidal S., Gros P. Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila. Nat. Genet. 2003, 33:55-60.
45. Wright E.K., Goodart S.A., Growney J.D., Hadinoto V., Endrizzi M.G., Long E.M., Sadigh K., Abney A.L., Bernstein-Hanley I., Dietrich W.F. Naip5 affects host susceptibility to the intracellular pathogen Legionella pneumophila. Curr. Biol. 2003, 13:27-36.
46. Shin H., Renatus M., Eckelman B.P., Nunes V.A., Sampaio C.A., Salvesen G.S. The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem. J. 2005, 385:1-10.
47. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., Day C.L., Tikoo A., Burke R., Wrobel C., Moritz R.L., Simpson R.J., Vaux D.L. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 2002, 277:445-454.
48. Yang Q.H., Church-Hajduk R., Ren J., Newton M.L., Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 2003, 17:1487-1496.
49. Shiozaki E.N., Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem. Sci. 2004, 29:486-494.
50. Verhagen A.M., Kratina T.K., Hawkins C.J., Silke J., Ekert P.G., Vaux D.L. Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. Cell Death Differ. 2007, 14:348-357.
51. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., Korneluk R.G. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat. Cell Biol. 2001, 3:128-133.
52. Arora V., Cheung H.H., Plenchette S., Micali O.C., Liston P., Korneluk R.G. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J. Biol. Chem. 2007, 282:26202-26209.
53. Yu L.F., Wang J., Zou B., Lin M.C., Wu Y.L., Xia H.H., Sun Y.W., Gu Q., He H., Lam S.K., Kung H.F., Wong B.C. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. Cancer 2007.
54. Plenchette S., Cheung H.H., Fong W.G., LaCasse E.C., Korneluk R.G. The role of XAF1 in cancer. Curr. Opin. Investig. Drugs 2007, 8:469-476.
55. Vucic D., Stennicke H.R., Pisabarro M.T., Salvesen G.S., Dixit V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 2000, 10:1359-1366.
56. Gong J., Chen N., Zhou Q., Yang B., Wang Y., Wang X. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J. Clin. Pathol. 2005, 58:1081-1085.
57. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., Saccani G., Frati L., Agliano A.M. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann. Oncol. 2003, 14:85-90.
58. Kempkensteffen C., Hinz S., Christoph F., Krause H., Koellermann J., Magheli A., Schrader M., Schostak M., Miller K., Weikert S. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol. 2007, 28:132-138.
59. Crnkovic-Mertens I., Wagener N., Semzow J., Grone E.F., Haferkamp A., Hohenfellner M., Butz K., Hoppe-Seyler F. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol. Life Sci. 2007, 64:1137-1144.
60. Dynek J.N., Chan S.M., Liu J., Zha J., Fairbrother W.J., Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008, 68:3124-3132.
61. Hu Y., Cherton-Horvat G., Dragowska V., Baird S., Korneluk R.G., Durkin J.P., Mayer L.D., LaCasse E.C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 2003, 9:2826-2836.
62. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000, 60:5659-5666.
63. Bilim V., Kasahara T., Hara N., Takahashi K., Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer 2003, 103:29-37.
64. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
65. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., Mu D., Lucito R., Powers S., Lowe S.W. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
66. Akagi T., Motegi M., Tamura A., Suzuki R., Hosokawa Y., Suzuki H., Ota H., Nakamura S., Morishima Y., Taniwaki M., Seto M. A novel gene, MALT1 at 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999, 18:5785-5794.
67. Dierlamm J., Baens M., Stefanova-Ouzounova M., Hinz K., Wlodarska I., Maes B., Steyls A., Driessen A., Verhoef G., Gaulard P., Hagemeijer A., Hossfeld D.K., De Wolf-Peeters C., Marynen P. Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood 2000, 96:2215-2218.
68. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J.M., Hossfeld D.K., De Wolf-Peeters C., Hagemeijer A., Van den Berghe H., Marynen P. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6 associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609.
69. Morgan J.A., Yin Y., Borowsky A.D., Kuo F., Nourmand N., Koontz J.I., Reynolds C., Soreng L., Griffin C.A., Graeme-Cook F., Harris N.L., Weisenburger D., Pinkus G.S., Fletcher J.A., Sklar J. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 1999, 59:6205-6213.
70. Imoto I., Yang Z.Q., Pimkhaokham A., Tsuda H., Shimada Y., Imamura M., Ohki M., Inazawa J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001, 61:6629-6634.
71. Imoto I., Tsuda H., Hirasawa A., Miura M., Sakamoto M., Hirohashi S., Inazawa J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002, 62:4860-4866.
72. Isaacson P.G. Update on MALT lymphomas. Best Pract. Res. Clin. Haematol. 2005, 18:57-68.
73. Vucic D., Fairbrother W.J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 2007, 13:5995-6000.
74. Yang L., Mashima T., Sato S., Mochizuki M., Sakamoto H., Yamori T., Oh-Hara T., Tsuruo T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003, 63:831-837.
75. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
76. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 2002, 277:44236-44243.
77. Vucic D., Deshayes K., Ackerly H., Pisabarro M.T., Kadkhodayan S., Fairbrother W.J., Dixit V.M. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 2002, 277:12275-12279.
78. Ndubaku C., Cohen F., Varfolomeev E., Vucic D. Targeting inhibitor of apoptosis (IAP) proteins for therapeutic intervention. Future Med. Chem. 2009, 1:1509-1525.
79. Sun H., Nikolovska-Coleska Z., Yang C.Y., Qian D., Lu J., Qiu S., Bai L., Peng Y., Cai Q., Wang S. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc. Chem. Res. 2008, 41:1264-1277.
80. Gaither A., Porter D., Yao Y., Borawski J., Yang G., Donovan J., Sage D., Slisz J., Tran M., Straub C., Ramsey T., Iourgenko V., Huang A., Chen Y., Schlegel R., Labow M., Fawell S., Sellers W.R., Zawel L. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 2007, 67:11493-11498.
81. Flygare J.A., Fairbrother W.J. Small-molecule pan-IAP antagonists: a patent review. Expert Opin. Ther. Pat. 2010, 20:251-267.
82. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 2004, 305:1471-1474.
83. Nikolovska-Coleska Z., Meagher J.L., Jiang S., Kawamoto S.A., Gao W., Yi H., Qin D., Roller P.P., Stuckey J.A., Wang S. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal. Biochem. 2008, 374:87-98.
84. Sun H., Nikolovska-Coleska Z., Lu J., Meagher J.L., Yang C.Y., Qiu S., Tomita Y., Ueda Y., Jiang S., Krajewski K., Roller P.P., Stuckey J.A., Wang S. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 2007, 129:15279-15294.
85. Gao Z., Tian Y., Wang J., Yin Q., Wu H., Li Y.M., Jiang X. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J. Biol. Chem. 2007, 282:30718-30727.
86. Varfolomeev E., Alicke B., Elliott J.M., Zobel K., West K., Wong H., Scheer J.M., Ashkenazi A., Gould S.E., Fairbrother W.J., Vucic D. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J. Biol. Chem. 2009, 284:34553-34560.
87. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., Harran P., Wang X. Autocrine TNFalpha signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
88. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
89. Ndubaku C., Varfolomeev E., Wang L., Zobel K., Lau K., Elliott L.O., Maurer B., Fedorova A.V., Dynek J.N., Koehler M., Hymowitz S.G., Tsui V., Deshayes K., Fairbrother W.J., Flygare J.A., Vucic D. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 2009, 4:557-566.
90. Wu T.Y., Wagner K.W., Bursulaya B., Schultz P.G., Deveraux Q.L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 2003, 10:759-767.
91. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott F.L., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh J.M., Houghten R.A., Reed J.C. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5:25-35.
92. J.R. Infante, E.C. Dees, H.A. Burris III, L. Zawel, J.A. Sager, C. Stevenson, K. Clarke, S. Dhuria, D. Porter, S.K. Sen, E. Zannou, S. Sharma, R.B. Cohen, A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer, in: The Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, 2010.
93. Dai Y., Liu M., Tang W., DeSano J., Burstein E., Davis M., Pienta K., Lawrence T., Xu L. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 2008, 14:7701-7710.
94. Dineen S.P., Roland C.L., Greer R., Carbon J.G., Toombs J.E., Gupta P., Bardeesy N., Sun H., Williams N., Minna J.D., Brekken R.A. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010, 70:2852-2861.
95. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Gschwend J.E., Simmet T., Debatin K.M., Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 2008, 68:7956-7965.
96. Ziegler D.S., Wright R.D., Kesari S., Lemieux M.E., Tran M.A., Jain M., Zawel L., Kung A.L. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J. Clin. Invest. 2008, 118:3109-3122.
97. Dai Y., Liu M., Tang W., Li Y., Lian J., Lawrence T.S., Xu L. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 2009, 9:392.
98. Dean E.J., Ward T., Pinilla C., Houghten R., Welsh K., Makin G., Ranson M., Dive C. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Br. J. Cancer 2010, 102:97-103.
99. Lecis D., Drago C., Manzoni L., Seneci P., Scolastico C., Mastrangelo E., Bolognesi M., Anichini A., Kashkar H., Walczak H., Delia D. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br. J. Cancer 2010, 102:1707-1716.